Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation

Vascular disrupting agents (VDAs) have entered clinical trials for over 15 years. As the leading VDA, combretastatin A4 phosphate (CA4P) has been evaluated in combination with chemotherapy and molecular targeting agents among patients with ovarian cancer, lung cancer and thyroid cancer, but still re...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yewei, Wang, Shuncong, Zhao, Xiaohui, Feng, Yuanbo, Bormans, Guy, Swinnen, Johan, Oyen, Raymond, Huang, Gang, Ni, Yicheng, Li, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168934/
https://www.ncbi.nlm.nih.gov/pubmed/32024029
http://dx.doi.org/10.3390/diagnostics10020078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168934/
https://www.ncbi.nlm.nih.gov/pubmed/32024029
http://dx.doi.org/10.3390/diagnostics10020078

Ejemplares similares